PLXNC1 and melanoma: Furthermore, NRP2, PLXNC1 and PLXNB3 were also positively associated with cell sensitivity to Dabrafenib, which is the treatment for late-stage melanoma and metastatic non-small cell lung cancer with BRAF V600E or V600K mutations (Figure 5C and Table S5).